When researchers raised safety concerns over GlaxoSmithKline's diabetes drug Avandia this spring, they triggered a drop in the share price that has stirred deeper worries about the pharmaceutical group's financial health.
Recent performance below even that of the broader drug sector has sparked a fresh round of investor dissatisfaction and debate over ideas for a restructuring designed to release more value.
The options include the sale of non-core assets; full or partial divestment of pharmaceutical divisions; a broader overhaul of its operations; and the return of cash to shareholders through dividends and buy-backs.
More at the FT
Recent performance below even that of the broader drug sector has sparked a fresh round of investor dissatisfaction and debate over ideas for a restructuring designed to release more value.
The options include the sale of non-core assets; full or partial divestment of pharmaceutical divisions; a broader overhaul of its operations; and the return of cash to shareholders through dividends and buy-backs.
More at the FT
No comments:
Post a Comment